《大行報告》富瑞大幅下調京東健康(06618.HK)目標價至80元 評級「買入」
富瑞發表評級報告指,京東健康(06618.HK)去年銷售按年升52%至467億元人民幣,經調整後每股盈測按年升84%至0.83元人民幣。管理層表示,去年第四季及今年首季銷售表現強勁;在去年第四季高基數下,該行料公司今年收入按年增長約30%,而隨著收入組合優化,長遠毛利率或由現時約21%改善到25%至30%。該行預計,履約費用率保持穩定,但相信在近期內將會有更多投資於研發及營銷等方面。
該行將其目標價由184元大幅下調至80元,維持其評級為「買入」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.